**Covid-19 and Adrenal Insufficiency - Patient Advisory**

The PNA has been monitoring the unprecedented events taking place around the world.
During these uncertain times, we want to share as much information with our patient community as possible. 

Click on this link to read the advisory

Management of Agressive Pituitary Tumors

Presented by

Andrew Lin, MD
Neuro-Oncologist & Neurologist
Memorial Sloak Kettering Cancer Center

Description

Learning Objectives:
During the conversation I will be:
1) Defining aggressive pituitary tumors.
2) Reviewing the current treatment options for aggressive pituitary tumors.
3) Discussing experimental treatment options including a phase II trial investigating the activity of the immunotherapies nivolumab and ipilimumab.

Presenter Biography:
Dr. Lin is a neuro-oncologist at Memorial Sloan Kettering Cancer Center (MSK) and a member of the Multidisciplinary Pituitary & Skull Base Tumor Center. In collaboration with his colleagues in endocrine, neurosurgery, and radiation oncology, he treat patients with aggressive pituitary tumors, who are resistant to conventional treatments (i.e. surgery and radiation), with chemotherapy. Dr. Lin and the team at Memorial Sloan Kettering have published several research articles on pituitary tumors and opened several clinical trials.

Leave a comment

You are commenting as guest.